Pharma

Outlook Therapeutics Shares Rise After FDA Clears Lytenava for Wet AMD Treatment

Outlook Therapeutics shares surged after the FDA cleared Lytenava for treating wet AMD, the first approved bevacizumab eye treatment in the U.S. The stock jumped nearly 9% pre-market.

July 27, 2026